AnaptysBio sells Zejula royalty rights to DRI Healthcare for $35M upfront

ANAPTYSBIO, INC

Received $35M upfront from DRI for all future Zejula royalties from GSK (effective July 2022).
Eligible for additional $10M milestone if Zejula approved for endometrial cancer by Dec 31, 2025.
Current effective royalty rate is 0.5% of global Zejula net sales.
Agreement includes customary covenants; Purchase Agreement to be filed in Q3 2022 10-Q.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.